SEC Form 4 · accession 0001193125-26-386782
Kailera Therapeutics, Inc. · KLRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Nur Nicholson
Officer — Chief Technology Officer
Period of report
Sep 7, 2026
Accepted (ET)
Sep 9, 2026 · 7:29 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0002096997
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $16.23 | Sep 7, 2026 | A | 220,000 | A | — | Sep 7, 2036 | Common Stock | 220,000 | 220,000 | D |
Explanation of responses
- F1The options vest and become exercisable as to 25% of the underlying shares on August 31, 2027 and thereafter in 36 substantially equal monthly installments, subject to the Reporting Person's continued service through each such vesting date.